Advertisement

Cellular and Molecular Life Sciences

, Volume 74, Issue 1, pp 129–140 | Cite as

Cystic fibrosis: a clinical view

  • Carlo Castellani
  • Baroukh M. Assael
Multi-author review

Abstract

Cystic fibrosis (CF), a monogenic disease caused by mutations in the CFTR gene on chromosome 7, is complex and greatly variable in clinical expression. Airways, pancreas, male genital system, intestine, liver, bone, and kidney are involved. The lack of CFTR or its impaired function causes fat malabsorption and chronic pulmonary infections leading to bronchiectasis and progressive lung damage. Previously considered lethal in infancy and childhood, CF has now attained median survivals of 50 years of age, mainly thanks to the early diagnosis through neonatal screening, recognition of mild forms, and an aggressive therapeutic attitude. Classical treatment includes pancreatic enzyme replacement, respiratory physiotherapy, mucolitics, and aggressive antibiotic therapy. A significant proportion of patients with severe symptoms still requires lung or, less frequently, liver transplantation. The great number of mutations and their diverse effects on the CFTR protein account only partially for CF clinical variability, and modifier genes have a role in modulating the clinical expression of the disease. Despite the increasing understanding of CFTR functioning, several aspects of CF need still to be clarified, e.g., the worse outcome in females, the risk of malignancies, the pathophysiology, and best treatment of comorbidities, such as CF-related diabetes or CF-related bone disorder. Research is focusing on new drugs restoring CFTR function, some already available and with good clinical impact, others showing promising preliminary results that need to be confirmed in phase III clinical trials.

Keywords

Cystic fibrosis CFTR Genotype Phenotype Precision medicine 

References

  1. 1.
    Andersen DH (1938) Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child 56:344–399CrossRefGoogle Scholar
  2. 2.
    http://www.cysticfibrosis.ca/. Accessed 1 Aug 2016
  3. 3.
    Hurley MN, McKeever TM, Prayle AP, Fogarty AW, Smyth AR (2014) Rate of improvement of CF life expectancy exceeds that of general population–observational death registration study. J Cyst Fibros 13:410–415PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Burgel P-R, Bellis G, Olesen H, Viviani L, Zolin A, Blasi F, Elborn JS (2015) Future trends in cystic fibrosis demography in 34 European countries. Euro Respir J 46:133–141CrossRefGoogle Scholar
  5. 5.
    Plant BJ, Goss CH, Plant WD, Bell SC (2013) Management of comorbidities in older patients with cystic fibrosis. Lancet Respir Med 1:164–174PubMedCrossRefGoogle Scholar
  6. 6.
    Gadsby DC, Vergani P, Csanády L (2006) The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 440:477–483PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Keiser NW, Engelhardt JF (2011) New animal models of cystic fibrosis: what are they teaching us? Curr Opin Pulm Med 17:478–483PubMedPubMedCentralGoogle Scholar
  8. 8.
    Ciro D, Padoan R, Blau H, Marostica A, Fuoti M, Volpi S, Pilotta A, Meyerovitch J, Sher D, Assael BM (2013) Growth retardation and reduced growth hormone secretion in cystic fibrosis. Clinical observations from three CF centers. J Cyst Fibros 12:165–169PubMedCrossRefGoogle Scholar
  9. 9.
    Jin R, Hodges CA, Drumm ML, Palmert MR (2006) The cystic fibrosis transmembrane conductance regulator (CFTR) modulates the timing of puberty in mice. J Med Genet 43:e29PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Delion M, Braux J, Jourdain ML, Guillaume C, Bour C, Gangloff S, Le Pimpec-Barthes F, Sermet-Gaudelus I, Jacquot J, Velard F (2016) Over-expression of RANKL in osteoblasts: a possible mechanism of susceptibility to bone disease in cystic fibrosis. J Pathol. doi: 10.1002/path.4753 PubMedGoogle Scholar
  11. 11.
    Gibney EM, Goldfarb DS (2003) The association of nephrolithiasis with cystic fibrosis. Am J Kidney Dis 42:1–11PubMedCrossRefGoogle Scholar
  12. 12.
    Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB (2013) Cancer risk in cystic Fibrosis: A 20-year nationwide study from the United States. J Natl Cancer Inst 105:122–129PubMedCrossRefGoogle Scholar
  13. 13.
    Billings JL, Dunitz JM, McAllister S, Herzog T, Bobr A, Khoruts A (2014) Early colon screening of adult patients with cystic fibrosis reveals high incidence of adenomatous colon polyps. J Clin Gastroenterol 48:e85–e88PubMedCrossRefGoogle Scholar
  14. 14.
    Azimi A (2015) Cystic fibrosis could survive cholera, choleraics could survive cystic fibrosis, hypothesis that explores new horizon in treatmnet of cystic fibrosis. Med Hypoth 85:715–717CrossRefGoogle Scholar
  15. 15.
    Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N et al (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245:1059–1065PubMedCrossRefGoogle Scholar
  16. 16.
    Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073–1080PubMedCrossRefGoogle Scholar
  17. 17.
    Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066–1073PubMedCrossRefGoogle Scholar
  18. 18.
    Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, Ramalho AS, Amaral MD, Dorfman R, Zielenski J, Masica DL, Karchin R, Millen L, Thomas PJ, Patrinos GP, Corey M, Lewis MH, Rommens JM, Castellani C, Penland CM, Cutting GR (2013) Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 45:1160–1167PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Tsui LC (1992) The spectrum of cystic fibrosis mutations. Trends Genet 8:392–398PubMedCrossRefGoogle Scholar
  20. 20.
    Welsh MJ, Smith AE (1993) Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73:1251–1254PubMedCrossRefGoogle Scholar
  21. 21.
    Zielenski J, Tsui LC (1995) Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 29:777–807PubMedCrossRefGoogle Scholar
  22. 22.
    Bombieri C, Seia M, Castellani C (2015) Genotypes and Phenotypes in Cystic Fibrosis and Cystic Fibrosis Transmembrane Regulator-Related DisordersSemin Respir. Crit Care Med 36:1–14Google Scholar
  23. 23.
    Andersen DH (1958) Cystic fibrosis of the pancreas. J Chronic Dis 7:58–90PubMedCrossRefGoogle Scholar
  24. 24.
    Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M, Bareil C, Bilton D, Castellani C, Cuppens H, Cutting GR, Drevínek P, Farrell P, Elborn JS, Jarvi K, Kerem B, Kerem E, Knowles M, Macek M Jr, Munck A, Radojkovic D, Seia M, Sheppard DN, Southern KW, Stuhrmann M, Tullis E, Zielenski J, Pignatti PF, Ferec C (2011) Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros 10(Suppl 2):S86–S102PubMedCrossRefGoogle Scholar
  25. 25.
    Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, Darrah RJ, Dorfman R, Sandford AJ, Corey M, Zielenski J, Durie P, Goddard K, Yankaskas JR, Wright FA, Knowles MR, Gene Modifier Study Group (2005) Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 353:1443–1453PubMedCrossRefGoogle Scholar
  26. 26.
    Hubert HB, Fabsitz RR, Feinleib M, Gwinn C (1982) Genetic and environmental influences on pulmonary function in adult twins. Am Rev Respir Dis. 125:409–415PubMedGoogle Scholar
  27. 27.
    McClearn GE, Svartengren M, Pedersen NL, Heller DA, Plomin R (1994) Genetic and environmental influences on pulmonary function in aging Swedish twins. J Gerontol. 49:264–268PubMedCrossRefGoogle Scholar
  28. 28.
    Tümmler B., Stanke F. (2014) Genetic and environmental modifiers of cystic fibrosis. In: Mall MA, Elborn JS (eds) Cystic fibrosis. ERS MonographsGoogle Scholar
  29. 29.
    Knowles MR, Drumm M. (2012) The influence of genetics on cystic fibrosis phenotypes. Cold Spring Harb Perspect Med 2(12):a009548Google Scholar
  30. 30.
    Yarden J, Radojkovic D, De Boeck K, Macek M Jr, Zemkova D, Vavrova V, Vlietinck R, Cassiman JJ, Cuppens H (2004) Polymorphisms in the mannose binding lectin gene affect the cystic fibrosis pulmonary phenotype. J Med Genet 41:629–633PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Hillian AD, Londono D, Dunn JM, Goddard KAB, Pace RG, Knowles MR, Drumm ML, CF Gene Modifier Study Group (2008) Modulation of cystic fibrosis lung disease by variants in interleukin-8. Genes Immun 9:501–508PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Chiarini M, Sabelli C, Melotti P, Garlanda C, Savoldi G, Mazza C, Padoan R, Plebani A, Mantovani A, Notarangelo LD, Assael BM, Badolato R (2010) PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Genes Immun 11:665–670PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun L, Berthiaume Y, Cutler D, Cojocaru A, Collaco JM et al (2011) Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 43:539–546PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Green DM, Collaco JM, McDougal KE, Naughton KM, Blackman SM, Cutting GR (2012) Heritability of respiratory infection with Pseudomonas aeruginosa in cystic fibrosis. J Pediatr 161:290–295PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Khan TZ, Wagener JS, Bost T, Bost T, Martinez J, Accurso FJ, Riches DW (1995) Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151:1075–1082PubMedGoogle Scholar
  36. 36.
    Schultz A, Stick S (2015) Early pulmonary inflammation and lung damage in children with cystic fibrosis. Respirology 20:569–578PubMedCrossRefGoogle Scholar
  37. 37.
    Cohen TS, Prince A (2012) Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 18:509–519PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Sorio C, Montresor A, Bolomini-Vittori M, Caldrer S, Rossi B, Dusi S, Angiari S, Johansson JE, Vezzalini M, Leal T, Calcaterra E, Assael BM, Melotti P, Laudanna C (2016) Mutations of cystic fibrosis transmembrane conductance regulator gene cause a monocyte-selective adhesion deficiency. Am J Respir Crit Care Med 193:1123–1133PubMedCrossRefGoogle Scholar
  39. 39.
    Grabiec AM, Hussell T (2016) The role of airway macrophages in apoptotic cell clearance following acute and chronic lung inflammation. Semin Immunopathol. 38:409–423PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Lee JM, Leach ST, Katz T, Day AS, Jaffe A, Ooi CY (2012) Update of faecal markers of inflammation in children with cystic fibrosis. Mediators Inflamm 2012:948367PubMedPubMedCentralGoogle Scholar
  41. 41.
    Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW 3rd (2008) Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 153:S4–S14PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J, Sinaasappel M, on behalf of the Diagnostic Working Group (2006) Cystic fibrosis: terminology and diagnostic algorithms. Thorax 61:627–635PubMedCrossRefGoogle Scholar
  43. 43.
    Knowles MR, Paradiso AM, Boucher RC (1995) In vivo nasal potential techniques and protocols for the assessment of the efficiency of gene transfer in cystic fibrosis. Hum Gene Ther 6:445–455PubMedCrossRefGoogle Scholar
  44. 44.
    De Jonge HR, Ballmann M, Veeze H, Bronsveld I, Stanke F, Tümmler B, Sinaasappel M (2004) Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J Cyst Fibros 3:159–163PubMedCrossRefGoogle Scholar
  45. 45.
    De Oronzo MA (2011) Hyperechogenic fetal bowel: an ultrasonographic marker for adverse fetal and neonatal outcome? J Prenatal Med 5:9–13Google Scholar
  46. 46.
    Castellani C, Massie J, Sontag M, Southern KW (2016) Newborn screening for cystic fibrosis. Lancet Respir Med. doi: 10.1016/S2213-2600(16)00053-9
  47. 47.
    Quinton P (2006) Cystic fibrosis: lessons from the sweat gland. Physiology 22:212–225CrossRefGoogle Scholar
  48. 48.
    Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, Murray CP, Stick SM, Investigators ARESTCF (2013) Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 368:1963–1970PubMedCrossRefGoogle Scholar
  49. 49.
    Sly PD, Brennan S (2004) Detecting early lung disease in cystic fibrosis: are current techniques sufficient? Thorax 59:1008–1010PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Tiddens HA (2002) Detecting early structural lung damage in cystic fibrosis. Pediatr Pulmonol 34:228–231PubMedCrossRefGoogle Scholar
  51. 51.
    Mott LS, Graniel KG, Park J, de Klerk NH, Sly PD, Murray CP, Tiddens HA, Stephen MS, Arest CF (2013) Assessment of early bronchiectasis in young children with cystic fibrosis is dependent on lung volume. Chest 144:1193–1198PubMedCrossRefGoogle Scholar
  52. 52.
    Simpson SJ, Ranganathan S, Park J, Turkovic L, Robins-Browne RM, Skoric B, Ramsey KA, Rosenow T, Banton GL, Berry L, Stick SM, Hall GL, Arest CF (2015) Progressive ventilation inhomogeneity in infants with cystic fibrosis after pulmonary infection. Eur Respir J 46:1680–1690PubMedCrossRefGoogle Scholar
  53. 53.
    Tang AC, Turvey SE, Alves MP, Regamey N, Tümmler B, Hartl D (2014) Current concepts: host-pathogen interactions in cystic fibrosis airways disease. Eur Respir Rev 23:320–332PubMedCrossRefGoogle Scholar
  54. 54.
    Pezzulo AA, Tang XX, Hoegger MJ, Alaiwa MH, Ramachandran S, Moninger TO, Karp PH, Wohlford-Lenane CL, Haagsman HP, van Eijk M, Bánfi B, Horswill AR, Stoltz DA, McCray PB Jr, Welsh MJ, Zabner J (2012) Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487:109–113PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Huang YJ, LiPuma JJ (2016) The Microbiome in Cystic Fibrosis. Clin Chest Med 37:59–67PubMedCrossRefGoogle Scholar
  56. 56.
    Justicia JL, Solé A, Quintana-Gallego E, Gartner S, de Gracia J, Prados C, Máiz L (2015) Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice. Expert Rev Respir Med. 9:183–194PubMedCrossRefGoogle Scholar
  57. 57.
    Döring G, Flume P, Heijerman H, Elborn JS; Consensus Study Group (2012) Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 1:461–479Google Scholar
  58. 58.
    Stenbit AE, Flume PA (2011) Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 17:442–447PubMedGoogle Scholar
  59. 59.
    Walter S, Gudowius P, Bosshammer J, Römling U, Weissbrodt H, Schürmann W, von der Hardt H, Tümmler B (1997) Epidemiology of chronic Pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis. Thorax 52:318–321PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Hansen SK, Rau MH, Johansen HK, Ciofu O, Jelsbak L, Yang L, Folkesson A, Jarmer HO, Aanæs K, von Buchwald C, Høiby N, Molin S (2012) Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J 6:31–45PubMedCrossRefGoogle Scholar
  61. 61.
    Illing EA, Woodworth BA (2014) Management of the upper airway in cystic fibrosis. Curr Opin Pulm Med. 20:623–631PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    De Lisle RC, Borowitz D (2013) The Cystic Fibrosis Intestine. Cold Spring Harb Perspect Med 3:a009753PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Cipolli M, Castellani C, Wilcken B, Massie J, McKay K, Gruca M, Tamanini A, Assael MB, Gaskin K (2007) Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening. Arch Dis Child 92:842–846PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Daftary A, Acton J, Heubi J, Amin R (2006) Fecal elastase-1: utility in pancreatic function in cystic fibrosis. J Cyst Fibros 5:71–76PubMedCrossRefGoogle Scholar
  65. 65.
    Dupuis A, Keenan K, Ooi CY, Dorfman R, Sontag MK, Naehrlich L, Castellani C, Strug LJ, Rommens JM, Gonska T (2016) Prevalence of meconium ileus marks the severity of mutations of the cystic fibrosistransmembrane conductance regulator (CFTR) gene. Genet Med 18:333–340Google Scholar
  66. 66.
    Raia V, Maiuri L, de Ritis G, de Vizia B, Vacca L, Conte R, Auricchio S, Londei M (2000) Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients. Pediatr Res 47:344–350PubMedCrossRefGoogle Scholar
  67. 67.
    Manor O, Levy R, Pope CE, Hayden HS, Brittnacher MJ, Carr R, Radey MC, Hager KR, Heltshe SL, Ramsey BW, Miller SI, Hoffman LR, Borenstein E (2016) Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis. Sci Rep. 6:22493PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Munck A (2014) Cystic fibrosis: evidence for gut inflammation. Int J Biochem Cell Biol 52:180–183PubMedCrossRefGoogle Scholar
  69. 69.
    Flass T, Narkewicz MR (2013) Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros 12:116–124PubMedCrossRefGoogle Scholar
  70. 70.
    Castaldo G, Fuccio A, Salvatore D, Raia V, Santostasi T, Leonardi S, Lizzi N, La Rosa M, Rigillo N, Salvatore F (2001) Liver expression in cystic fibrosis could be modulated by genetic factors different from the cystic fibrosis transmembrane regulator genotype. Am J Med Genet 98:294–297PubMedCrossRefGoogle Scholar
  71. 71.
    Pereira TN, Lewindon PJ, Greer RM, Hoskins AC, Williamson RM, Shepherd RW, Ramm GA (2012) Transcriptional basis for hepatic fibrosis in cystic fibrosis-associated liver disease. J Pediatr Gastroenterol Nutr 54:328–335PubMedCrossRefGoogle Scholar
  72. 72.
    Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR, Gene Modifier Study Group (2009) Genetic modifiers of liver disease in cystic fibrosis. JAMA 302:1076–1083PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Kelly A, Moran A (2013) Update on cystic fibrosis-related diabetes. J Cyst Fibros 12:318–331. doi: 10.1016/j.jcf.2013.02.008 (Erratum. In: J Cyst Fibros. 2014;13:119) PubMedCrossRefGoogle Scholar
  74. 74.
    Sermet-Gaudelus I, Bianchi ML, Garabédian M, Aris RM, Morton A, Hardin DS, Elkin SL, Compston JE, Conway SP, Castanet M, Wolfe S, Haworth CS (2011) European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros 10(Suppl 2):S16–S23PubMedCrossRefGoogle Scholar
  75. 75.
    Aris RM, Ontjes DA, Buell HE, Blackwood AD, Lark RK, Caminiti M, Brown SA, Renner JB, Chalermskulrat W, Lester GE (2002) Osteoporos Int 13(2):151–157PubMedCrossRefGoogle Scholar
  76. 76.
    Shead EF, Haworth CS, Condliffe AM, McKeon DJ, Scott MA, Compston JE (2007) Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 62:650–651PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Yu J, Chen Z, Ni Y, Li Z (2012) CFTR mutations in men with congenital bilateral absence of the vas deferens (CBAVD): a systemic review and meta-analysis. Hum Reprod 27:25–35PubMedCrossRefGoogle Scholar
  78. 78.
    Quinzii C, Castellani C (2000) The cystic fibrosis transmembrane regulator gene and male infertility. J Endocrinol Invest 23:684–689PubMedCrossRefGoogle Scholar
  79. 79.
    Assael BM, Casazza G, Iansa P, Volpi S, Milani S (2009) Growth and long-term lung function in cystic fibrosis: a longitudinal study of patients diagnosed by neonatal screening. Pediatr Pulmonol 44:209–215PubMedCrossRefGoogle Scholar
  80. 80.
    Rogan MP, Reznikov LR, Pezzulo AA, Gansemer ND, Samuel M, Prather RS, Zabner J, Fredericks DC, McCray PB Jr, Welsh MJ, Stoltz DA (2010) Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth. Proc Natl Acad Sci U S A. 107:20571–20575PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Conway S, Balfour-Lynn IM, De Rijcke K, Drevinek P, Foweraker J, Havermans T, Heijerman H, Lannefors L, Lindblad A, Macek M, Madge S, Moran M, Morrison L, Morton A, Noordhoek J, Sands D, Vertommen A, Peckham D (2014) European Cystic Fibrosis Society Standards of Care: framework for the Cystic Fibrosis Centre. J Cyst Fibros 13(Suppl 1):S3–S22PubMedCrossRefGoogle Scholar
  82. 82.
    Corey M, McLaughlin FJ, Williams M, Levison H (1988) A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 41:583–591PubMedCrossRefGoogle Scholar
  83. 83.
    Turck D, Braegger CP, Colombo C, Declercq D, Morton A, Pancheva R, Robberecht E, Stern M, Strandvik B, Wolfe S, Schneider SM, Wilschanski M (2016) ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr. 35:557–577PubMedCrossRefGoogle Scholar
  84. 84.
    Maqbool A, Schall JI, Gallagher PR, Zemel BS, Strandvik B, Stallings VA (2012) Relation between dietary fat intake type and serum fatty acid status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 55:605–611PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Strandvik B (2010) Fatty acid metabolism in cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids 83:121–129PubMedCrossRefGoogle Scholar
  86. 86.
    Maqbool A, Schall JI, Garcia-Espana JF, Zemel BS, Strandvik B, Stallings VA (2008) Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 4:635–644CrossRefGoogle Scholar
  87. 87.
    van Egmond AW, Kosorok MR, Koscik R, Laxova A, Farrell PM (1996) Effect of linoleic acid intake on growth of infants with cystic fibrosis. Am J Clin Nutr 63:746–752PubMedGoogle Scholar
  88. 88.
    Morrell MR, Pilewski JM (2016) Lung transplantation for cystic fibrosis. Clin Chest Med 37:127–138Google Scholar
  89. 89.
    Lynch JP 3rd, Sayah DM, Belperio JA, Weigt SS (2015) Lung transplantation for cystic fibrosis: results, indications, complications, and controversies. Semin Respir Crit Care Med. 36:299–320PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Leeuwen L, Fitzgerald DA, Gaskin KJ (2014) Liver disease in cystic fibrosis. Paediatr Respir Rev 15:69–74PubMedGoogle Scholar
  91. 91.
    Hughes A, Adil EA (2015) What is the role of endoscopic sinus surgery in adult patients with cystic fibrosis? Laryngoscope 125:2018–2020PubMedCrossRefGoogle Scholar
  92. 92.
    Lands LC, Milner R, Cantin AM, Manson D, Corey M (2007) High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 151:249–254PubMedCrossRefGoogle Scholar
  93. 93.
    Spagnolo P, Fabbri LM, Bush A (2013) Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 42:239–251PubMedCrossRefGoogle Scholar
  94. 94.
    Southern KW, Barker PM, Solis-Moya A, Patel L (2012) Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 11:CD002203Google Scholar
  95. 95.
    Lee TW, Southern KW, Perry LA, Penny-Dimri JC, Aslam AA (2016) Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease. Cochrane Database Syst Rev 17:CD005599. doi: 10.1002/14651858.CD005599.pub5
  96. 96.
    Oakland M, Sinn PL, McCray PB Jr (2012) Advances in cell and gene-based therapies for cystic fi brosis lung disease. Mol Ther 20:1108–1115PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Alton EW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, Boyd AC, Brand J, Buchan R, Calcedo R, Carvelli P, Chan M, Cheng SH, Collie DD, Cunningham S, Davidson HE, Davies G, Davies JC, Davies LA, Dewar MH, Doherty A, Donovan J, Dwyer NS, Elgmati HI, Featherstone RF, Gavino J, Gea-Sorli S, Geddes DM, Gibson JS, Gill DR, Greening AP, Griesenbach U, Hansell DM, Harman K, Higgins TE, Hodges SL, Hyde SC, Hyndman L, Innes JA, Jacob J, Jones N, Keogh BF, Limberis MP, Lloyd-Evans P, Maclean AW, Manvell MC, McCormick D, McGovern M, McLachlan G, Meng C, Montero MA, Milligan H, Moyce LJ, Murray GD, Nicholson AG, Osadolor T, Parra-Leiton J, Porteous DJ, Pringle IA, Punch EK, Pytel KM, Quittner AL, Rivellini G, Saunders CJ, Scheule RK, Sheard S, Simmonds NJ, Smith K, Smith SN, Soussi N, Soussi S, Spearing EJ, Stevenson BJ, Sumner-Jones SG, Turkkila M, Ureta RP, Waller MD, Wasowicz MY, Wilson JM, Wolstenholme-Hogg P, UK Cystic Fibrosis Gene Therapy Consortium (2015) Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 3:684–691PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, Brass-Ernst L (2002) Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 6:119–126PubMedCrossRefGoogle Scholar
  99. 99.
    Griese M, Kappler M, Eismann C, Ballmann M, Junge S, Rietschel E, van Koningsbruggen-Rietschel S, Staab D, Rolinck-Werninghaus C, Mellies U, Köhnlein T, Wagner T, König S, Teschler H, Heuer HE, Kopp M, Heyder S, Hammermann J, Küster P, Honer M, Mansmann U, Beck-Speier I, Hartl D, Fuchs C, Glutathione Study Group, Hector A (2013) Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med. 188:83–89PubMedCrossRefGoogle Scholar
  100. 100.
    Adams C, Icheva V, Deppisch C, Lauer J, Herrmann G, Graepler-Mainka U, Heyder S, Gulbins E, Riethmueller J (2016) Long-Term Pulmonal Therapy of Cystic Fibrosis-Patients with Amitriptyline. Cell Physiol Biochem 39:565–572PubMedCrossRefGoogle Scholar
  101. 101.
    Nährlich L, Mainz JG, Adams C, Engel C, Herrmann G, Icheva V, Lauer J, Deppisch C, Wirth A, Unger K, Graepler-Mainka U, Hector A, Heyder S, Stern M, Döring G, Gulbins E, Riethmüller J (2013) Therapy of CF-patients with amitriptyline and placebo–a randomised, double-blind, placebo-controlled phase IIb multicenter, cohort-study. Cell Physiol Biochem 31:505–512PubMedCrossRefGoogle Scholar
  102. 102.
    Becker KA, Riethmüller J, Lüth A, Döring G, Kleuser B, Gulbins E (2010) Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am J Respir Cell Mol Biol 42:716–724PubMedCrossRefGoogle Scholar
  103. 103.
    Riethmüller J, Anthonysamy J, Serra E, Schwab M, Döring G, Gulbins E (2009) Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. Cell Physiol Biochem 24:65–72PubMedCrossRefGoogle Scholar
  104. 104.
    Dey I, Shah K, Bradbury NA (2016) Natural Compounds as Therapeutic Agents in the Treatment Cystic Fibrosis. J Genet Syndr Gene Ther 7pii: 284Google Scholar
  105. 105.
    Moss RB (2013) Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr 162:676–680PubMedCrossRefGoogle Scholar
  106. 106.
    ClinicalTrials.gov Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF) Last verified July 2016Google Scholar
  107. 107.
    Fayon M, Kent L, Bui S, Dupont L, Sermet I (2014) European Cystic Fibrosis Society Clinical Trial Network Standardisation Committee. Clinimetric properties of bronchoalveolar lavage inflammatory markers in cystic fibrosis. Eur Respir J 43:610–626PubMedCrossRefGoogle Scholar
  108. 108.
    Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A, Kerem B, Kerem E (2000) A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 161:860–865PubMedCrossRefGoogle Scholar
  109. 109.
    Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E (2003) Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 349:1433–1441PubMedCrossRefGoogle Scholar
  110. 110.
    Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, Mogenet A, Roussel D, Fritsch J, Hanssens L, Hirawat S, Miller NL, Constantine S, Reha A, Ajayi T, Elfring GL, Miller LL (2010) Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 182:1262–1272PubMedCrossRefGoogle Scholar
  111. 111.
    De Boeck K, Kent L, Davies J, Derichs N, Amaral M, Rowe SM, Middleton P, de Jonge H, Bronsveld I, Wilschanski M, Melotti P, Danner-Boucher I, Boerner S, Fajac I, Southern K, de Nooijer RA, Bot A, de Rijke Y, de Wachter E, Leal T, Vermeulen F, Hug MJ, Rault G, Nguyen-Khoa T, Barreto C, Proesmans M, Sermet-Gaudelus I, European Cystic Fibrosis Society Clinical Trial Network Standardisation Committee (2013) CFTR biomarkers: time for promotion to surrogate end-point. Eur Respir J 4:203–216CrossRefGoogle Scholar
  112. 112.
    Dekkers JF, Berkers G, Kruisselbrink E, Vonk A, de Jonge HR, Janssens HM, Bronsveld I, van de Graaf EA, Nieuwenhuis EE, Houwen RH, Vleggaar FP, Escher JC, de Rijke YB, Majoor CJ, Heijerman HG, de Winter-de Groot KM, Clevers H, van der Ent CK, Beekman JM (2016) Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med 8:344ra84Google Scholar
  113. 113.
    Dekkers JF, Van Mourik P, Vonk AM, Kruisselbrink E, Berkers G, de Winter-de Groot KM, Janssens HM, Bronsveld I, van der Ent CK, de Beekman JM (2016) Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations. J Cyst Fibros. doi: 10.1016/j.jcf.2016.04.007
  114. 114.
    Dekkers JF, Gogorza Gondra RA, Kruisselbrink E, Vonk AM, Janssens HM, de Winter-de Groot KM, van der Ent CK, Beekman JM (2016) Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids. Eur Respir J. doi: 10.1183/13993003.01192-2015
  115. 115.
    Vidović D, Carlon MS, da Cunha MF, Dekkers JF, Hollenhorst MI, Bijvelds MJ, Ramalho AS, Van den Haute C, Ferrante M, Baekelandt V, Janssens HM, De Boeck K, Sermet-Gaudelus I, de Jonge HR, Gijsbers R, Beekman JM, Edelman A, Debyser Z (2016) rAAV-CFTRΔR Rescues the cystic fibrosis phenotype in human intestinal organoids and cystic fibrosis mice. Am J Respir Crit Care Med 193:288–298PubMedCrossRefGoogle Scholar
  116. 116.
    Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; Cystic Fibrosis Ataluren Study Group (2014) Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2:539–547CrossRefGoogle Scholar
  117. 117.
    Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365:1663–1672CrossRefGoogle Scholar
  118. 118.
    Whiting P, Al M, Burgers L, Westwood M, Ryder S, Hoogendoorn M, Armstrong N, Allen A, Severens H, Kleijnen J (2014) Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technol Assess 18:1–106CrossRefGoogle Scholar
  119. 119.
    Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M; VX11-770-110 (KONDUCT) Study Group (2015) Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 3:524–533CrossRefGoogle Scholar
  120. 120.
    De Boeck K, Munck A, Walker S, Faro A, Hiatt P, Gilmartin G, Higgins M (2014) Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 13:674–680PubMedCrossRefGoogle Scholar
  121. 121.
    Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group (2015) Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med 373:220–231CrossRefGoogle Scholar
  122. 122.
  123. 123.
    De Stefano D, Villella VR, Esposito S, Tosco A, Sepe A, De Gregorio F, Salvadori L, Grassia R, Leone CA, De Rosa G, Maiuri MC, Pettoello-Mantovani M, Guido S, Bossi A, Zolin A, Venerando A, Pinna LA, Mehta A, Bona G, Kroemer G, Maiuri L, Raia V (2014) Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy. 10:2053–2074PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Tosco A, De Gregorio F, Esposito S, De Stefano D, Sana I, Ferrari E, Sepe A, Salvadori L, Buonpensiero P, Di Pasqua A, Grassia R, Leone CA, Guido S, De Rosa G, Lusa S, Bona G, Stoll G, Maiuri MC, Mehta A, Kroemer G, Maiuri L, Raia V (2016) A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR. Cell Death Differ 23:1380–1393PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Hoffman LR, Ramsey BW (2013) Cystic fibrosis therapeutics: the road ahead. Chest 143:207–213PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Davis PB (2011) Therapy for cystic fibrosis—the end of the beginning? N Engl J Med 365:1734–1735PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  1. 1.Verona Cystic Fibrosis CentreVeronaItaly
  2. 2.Adult Cystic Fibrosis CenterMilanoItaly

Personalised recommendations